Bionote Targets Annual Revenue of About KRW 300 Billion by FY2030

Bitget2026/10/22 09:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bionote's Oct. 22, 2026, value-up plan targets fiscal 2030 revenue of about KRW 300 billion.
Targets also include a 30% operating margin and a price-to-book ratio of 1.2 times.
Growth plans include expanding diagnostic platforms, increasing US subsidiary sales and establishing local production capacity.
The strategy also calls for entering the antibody therapeutics market and expanding the life sciences business.
Shareholder returns include maintaining stable dividends, with cancellation of 500,000 treasury shares annually under consideration for three years starting in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bionote Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261022800687), on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bionote Targets Annual Revenue of About KRW 300 Billion by FY2030

You may also like

Crypto prices